Dompé US to pay $32 million over self-disclosed Oxervate co-pay kickbacks

By ··2 min read

Dompé U.S. Inc. has agreed to pay $32 million to resolve Department of Justice allegations that it used two patient assistance foundations to cover Medicare co-pays for its drug Oxervate between 2018 and 2021. The conduct was self-disclosed by its Italian parent, and the company admitted certain facts as part of the settlement.

Dompé U.S. Inc., the California-based subsidiary of Italian drugmaker Dompé farmaceutici S.p.A., has agreed to pay $32 million to resolve allegations that it violated the Anti-Kickback Statute and the False Claims Act, the Department of Justice announced on September 10, 2026. The government alleged that between 2018 and 2021 the company paid Medicare beneficiaries' co-pays for Oxervate, its treatment for neurotrophic keratitis, through two patient assistance foundations in order to induce purchases of the drug.

The Anti-Kickback Statute bars pharmaceutical manufacturers from offering or paying any remuneration, directly or indirectly, to induce Medicare patients to buy their products, and that prohibition extends to covering patients' co-payment obligations. As part of the resolution, Dompé admitted that around Oxervate's US launch in 2018, company employees expressed reservations about launching before a payment had been made to a foundation that covered the drug's co-pays. According to the department, two foundations opened funds that paid Oxervate co-pays after conversations with Dompé employees, and Dompé then contributed to those foundations. The company also admitted soliciting data from the foundations and from the specialty pharmacy that provided hub services for its patients, and that this data reached individuals involved in budgeting its foundation contributions.

The department said Dompé farmaceutici self-disclosed the conduct and that both the parent and the US subsidiary cooperated with the investigation. Both received credit under the department's guidelines for self-disclosure, cooperation and remediation in False Claims Act matters. The department noted that the claims resolved are allegations only and that there has been no determination of liability.

The case adds to a long line of federal actions against manufacturers that route money through ostensibly independent charities to subsidise their own products. The US Attorney's Office for the District of Massachusetts said it has recovered more than $1.4 billion from settlements and enforcement actions over drug company payments to purported charities. Assistant Attorney General Brett A. Shumate used the announcement to encourage companies that uncover improper payments to come forward voluntarily, signalling that self-disclosure credit remains a central part of FCA enforcement.

The settlement was negotiated by the Civil Division's Commercial Litigation Branch, Fraud Section, together with the US Attorney's Office for the District of Massachusetts and HHS-OIG. The department did not describe further proceedings against the company or any individuals, and did not state whether Dompé has entered into a corporate integrity agreement.

Cite this report

The Precedent. "Dompé US to pay $32 million over self-disclosed Oxervate co-pay kickbacks." September 19, 2026. https://theprecedent.org/article/dompe-us-to-pay-32-million-over-self-disclosed-oxervate-co-pay-kickbacks